#mdpijdad
LightNews LightNews
fzali.bsky.social
My latest review on #amyloid #PET & blood #biomarkers for #Alzheimer’s provides clinically oriented algorithm for integrating plasma p-tau217, amyloid PET, #tau, & #MRI for monitoring during anti-amyloid #immunotherapy.

Read here: www.mdpi.com/4171100

@mdpiopenaccess.bsky.social #mdpijdad
Clinical algorithm for multimodal monitoring of anti-amyloid immunotherapy in Alzheimer’s disease. Baseline evaluation begins with plasma p-tau217, followed by confirmation of amyloid pathology using amyloid PET or cerebrospinal fluid testing when needed. During treatment, plasma p-tau217 provides a group-level pharmacodynamic signal, while serial amyloid PET assesses fibrillar plaque burden over therapy-specific intervals. Follow-up combines amyloid PET for plaque-clearance assessment, tau PET or plasma MTBR-tau243 for downstream tau evaluation, and brain MRI for amyloid-related imaging abnormalities, including edema, effusions, microhemorrhages, and superficial siderosis. Multimodal findings are integrated with cognitive, functional, and clinical assessments to guide management.
November 3, 2026 at 5:40 AM